Drugs / efatutazone
efatutazone
also known as
CS-7017 · CS-7017 ANHYDROUS · Efatutazona · efatutazone dihydrochloride · EFATUTAZONE HYDROCHLORIDE · Inolitazone · inolitazone dihydrochloride
Small molecule targets PPARG via activation
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01504490 | Dec 2011 → Dec 2016 | plasma cell myeloma | Georgetown University | Terminated | No outcome recorded |
| Phase 1 | NCT01199068 | Jun 2010 → Dec 2011 | non-small cell lung carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT01199055 | Mar 2010 → Apr 2011 | non-small cell lung carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT00881569 | Mar 2009 → Mar 2011 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT00408434 | Nov 2006 → Feb 2010 | neoplasm | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00603941 | Jan 2008 → Dec 2011 | thyroid gland undifferentiated (anaplastic) carcinoma | Daiichi Sankyo | Terminated | No outcome recorded Stop: Enrollment |
| Phase 26 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT02249949 | Feb 2015 → Oct 2018 | liposarcoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT02152137 | Dec 2014 → Feb 2019 | thyroid gland undifferentiated (anaplastic) carcinoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT01101334 | Mar 2010 → Apr 2013 | non-small cell lung carcinoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00967616 | Sep 2009 → Apr 2013 | colorectal cancer | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00986440 | Jul 2009 → Oct 2012 | colorectal cancer | Daiichi Sankyo | Terminated | Met primary |
| Phase 2 | NCT00806286 | Dec 2008 → Jan 2012 | non-small cell lung carcinoma | Daiichi Sankyo | Completed | Missed primary |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | efatutazone | “Efatutazone (CS-7017), a novel peroxisome proliferator-activated receptor gamma (PPARγ) agonist, exerts anticancer activity in preclinical models.” PMID 22570147 ↗ May 2012 |
| Known as | CS-7017 | “In the safety portion of the study, subjects with metastatic non-small cell lung cancer will be treated with study drug (CS-7017) in combination with carboplatin and paclitaxel...” NCT00806286 ↗11“Efatutazone (CS-7017), a novel peroxisome proliferator-activated receptor gamma (PPARγ) agonist, exerts anticancer activity in preclinical models.” PMID 22570147 ↗ May 2012 “CS-7017, an experimental drug and paclitaxel chemotherapy in subjects with advanced anaplastic thyroid cancer.” NCT00603941 ↗ “CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered by mouth (PO) BID every 12 hours.” NCT00967616 ↗ |
| Known as | CS-7017 ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545280 ↗ |
| Known as | Efatutazona | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545280 ↗ |
| Known as | efatutazone dihydrochloride | “This phase II trial studies how well inolitazone dihydrochloride (efatutazone dihydrochloride) and paclitaxel work in treating patients with anaplastic thyroid cancer that has...” NCT02152137 ↗ |
| Known as | EFATUTAZONE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545280 ↗ |
| Known as | Inolitazone | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545280 ↗ |
| Known as | inolitazone dihydrochloride | “This phase II trial studies how well inolitazone dihydrochloride (efatutazone dihydrochloride) and paclitaxel work in treating patients with anaplastic thyroid cancer that has...” NCT02152137 ↗ |
| Action | Activate | “Efatutazone (CS-7017), a novel peroxisome proliferator-activated receptor gamma (PPARγ) agonist, exerts anticancer activity in preclinical models.” PMID 22570147 ↗ May 2012 |
| Modality | Small molecule | — CHEMBL3545280 ↗ |
| Route | Oral | “0.15 mg twice daily (BID) oral CS-7017” NCT00603941 ↗ |
| Target | PPARG | “Efatutazone (CS-7017), a novel peroxisome proliferator-activated receptor gamma (PPARγ) agonist, exerts anticancer activity in preclinical models.” PMID 22570147 ↗ May 2012 |